Incidence of febrile neutropenia with use of docetaxel plus cyclophosphamide (TC) for breast cancer.

被引：0
|
作者：
Patel, Kiran
Diergaarde, Brenda
Brufsky, Adam
Jankowitz, Rachel Catherine
Lembersky, Barry C.
Rastogi, Priya
Huggins-Puhalla, Shannon Leigh
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12073
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Cyclophosphamide/docetaxel/doxorubicinFatal febrile neutropenia: case report
    Reactions Weekly, 2019, 1782 (1) : 119 - 119
  • [22] Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
    Kimura, Yuri
    Sasada, Shinsuke
    Emi, Akiko
    Masumoto, Norio
    Kadoya, Takayuki
    Okada, Morihito
    SUPPORTIVE CARE IN CANCER, 2021, 29 (07) : 3507 - 3512
  • [23] Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review
    Ricardo Fernandes
    Sasha Mazzarello
    Carol Stober
    Lisa Vandermeer
    Shaan Dudani
    Mohamed F. K. Ibrahim
    Habeeb Majeed
    Kirstin Perdrizet
    Risa Shorr
    Brian Hutton
    Dean Fergusson
    Mark Clemons
    Breast Cancer Research and Treatment, 2017, 161 : 1 - 10
  • [24] Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
    Yuri Kimura
    Shinsuke Sasada
    Akiko Emi
    Norio Masumoto
    Takayuki Kadoya
    Morihito Okada
    Supportive Care in Cancer, 2021, 29 : 3507 - 3512
  • [25] The Incidence of Febrile Neutropenia in the First Course of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide with or without Pegfilgrastim.
    Jones, S.
    Paul, D.
    Sedlacek, S.
    Vukelja, S.
    Wilks, S. T.
    Stokoe, C.
    Osborne, C. R.
    Krekow, L.
    McIntyre, K.
    Holmes, F. A.
    Guerra, L.
    Zhan, F.
    Asmar, L.
    O'Shaughnessy, J.
    Blum, J. L.
    CANCER RESEARCH, 2011, 71
  • [26] Use of Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy for Breast Cancer
    Livi, L.
    Meattini, I.
    Cardillo, C. De Luca
    Scotti, V.
    Agresti, B.
    Franzese, C.
    Sanchez, L.
    Nori, J.
    Bertocci, S.
    Cassani, S.
    Bianchi, S.
    Cataliotti, L.
    Biti, G.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 36 - 39
  • [27] Docetaxel plus cyclophosphamide in adjuvant breast cancer - In reply
    Jones, Stephen E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) : 4327 - 4327
  • [28] Cyclophosphamide/docetaxel/doxorubicin Febrile neutropenia: 3 case reports
    Reactions Weekly, 2021, 1843 (1) : 126 - 126
  • [29] Avoiding the Use of Anthracyclines in the Adjuvant Therapy of Breast Cancer: The "TC" (Docetaxel and Cyclophosphamide) Regimen
    Fox, Kevin R.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (01) : 7 - 8
  • [30] Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review
    Fernandes, Ricardo
    Mazzarello, Sasha
    Stober, Carol
    Vandermeer, Lisa
    Dudani, Shaan
    Ibrahim, Mohamed F. K.
    Majeed, Habeeb
    Perdrizet, Kirstin
    Shorr, Risa
    Hutton, Brian
    Fergusson, Dean
    Clemons, Mark
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (01) : 1 - 10
12345